Popular Articles
Natural Remedies

Critical Health (Booth C3) Launches Innovative Diabetic Retinopathy Progression Biomarker Software Solution, RetmarkerDR, In The European Market
Critical Health will be launching RetmarkerDR, an innovative Diabetic Retinopathy (DR) progression biomarker software in the European market at the Euretina exhibition (Booth C3; 14th to 17th May; Acropolis Centre; Nice; France). Critical Health is a leading provider of innovative products that help prevent the loss of vision, mobility and cognitive skills in an ageing population.
generic viagra online
Dr. Reddy's Receives Approval For Three INDs And Announces Reorganization Of Its Drug Discovery Operations
Dr. Reddy"s announced that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of dyslipidemia, atherosclerosis and associated cardiovascular diseases. The compound shows potent elevation in HDL-C and reduction of atherosclerotic plaques in animals, and has a clean safety profile in preclinical studies. The two other IND"s are for the treatment of COPD and dyslipidemia.
News of the day
ChemGenex To Present Pivotal Data In T315I Positive CML Patients As Oral Presentation At ASCO
ChemGenex Pharmaceuticals Limited (ASX:CXS) (NASDAQ:CXSP) announced that updated clinical data from the registration-directed clinical trial of omacetaxine will be presented as an oral presentation at the forthcoming American Society of Clinical Oncology (ASCO) 45th Annual Meeting in Orlando, Florida.
Oncology

Classification Methods For Identifying The Neural Characterics Of Antidepressant Treatment

Depression is a major public health problem, and one of the most important challenges for psychiatrists is to determine whether an individual with depression should receive cognitive-behavioral therapy or treatment with antidepressant medication. A study by researchers from Emory University, presented at the Annual Meeting of the Organization for Human Brain Mapping in San Francisco, used brain imaging along with sophisticated statistical techniques to examine the differences in brain function that result from these two different kinds of treatment. Forty individuals with depression were scanned with magnetic resonance imaging after undergoing cognitive behavioral therapy or antidepressant therapy. The researchers found that they could distinguish the brain activity of individuals undergoing the two different treatments, and in particular that the two treatments differently affected the communication of the brain areas that are thought to play a role in depression, including the communication between the prefrontal cortex and the nucleus accumbens, and between the subgenual cingulate and the thalamus. The results provide a basis for future research that will try to predict which individuals will benefit from different treatments for depression. Authors: S. Chen, G. Derado, Y. Guo, F.D. Bowman, Emory University, Atlanta, GA, United States Organization for Human Brain Mapping


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):